Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Lynsey Fazal"'
Autor:
Neil T. Thompson, David R. Newell, Christopher Murray, Julie Irving, John Lyons, Eddy Freyne, Edward J. Lewis, Jose Cosme, Andrew Pike, Brent L. Graham, Lindsay A. Devine, Susanne Bethell, Abarna Thiru, Ruth Feltell, Darcey Miller, Maria Carr, Sharna Rich, Michael A. Batey, Christopher Hamlett, Michael Reader, Martyn Frederickson, Alistair O'Brien, Emma Vickerstaffe, Rajdeep K. Benning, Andrew Madin, Charlotte Griffiths Jones, Douglas Ross, Lynsey Fazal, Tim Perera, Patrick Angibaud, Peter King, Anne Cleasby, Valerio Berdini, Gordan Saxty, George Ward, Matthew Squires
We describe here the identification and characterization of 2 novel inhibitors of the fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases. The compounds exhibit selective inhibition of FGFR over the closely related VEGFR2 rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::605eebdec9c9d2137ffcbba68a3b82cd
https://doi.org/10.1158/1535-7163.c.6535227
https://doi.org/10.1158/1535-7163.c.6535227
Autor:
Neil T. Thompson, David R. Newell, Christopher Murray, Julie Irving, John Lyons, Eddy Freyne, Edward J. Lewis, Jose Cosme, Andrew Pike, Brent L. Graham, Lindsay A. Devine, Susanne Bethell, Abarna Thiru, Ruth Feltell, Darcey Miller, Maria Carr, Sharna Rich, Michael A. Batey, Christopher Hamlett, Michael Reader, Martyn Frederickson, Alistair O'Brien, Emma Vickerstaffe, Rajdeep K. Benning, Andrew Madin, Charlotte Griffiths Jones, Douglas Ross, Lynsey Fazal, Tim Perera, Patrick Angibaud, Peter King, Anne Cleasby, Valerio Berdini, Gordan Saxty, George Ward, Matthew Squires
PDF file - 475K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fe1a33d4a31585a984d85c6194526c9
https://doi.org/10.1158/1535-7163.22496319
https://doi.org/10.1158/1535-7163.22496319
Autor:
Vanessa Martins, Lynsey Fazal, Aram Oganesian, Alpesh Shah, Jessie Stow, Hugh Walton, Nicola Wilsher
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 52(8)
Paxlovid, a drug combining nirmatrelvir and ritonavir, was designed for the treatment of COVID-19 and its rapid development has led to emergency use approval by the FDA to reduce the impact of COVID-19 infection on patients.In order to overcome poten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee4ca0ff271dad1caf94488e5d4c9327
https://pubmed.ncbi.nlm.nih.gov/36537234
https://pubmed.ncbi.nlm.nih.gov/36537234
Autor:
Benoit Carbain, Keisha Hearn, Ildiko Maria Buck, Burcu Anil, Sarah J. Cully, Gianni Chessari, Jane A. Endicott, John Lunec, Neil T. Thompson, Juan Castro, Roger J. Griffin, Rhian S. Holvey, Karen Haggerty, Charlotte H. Revill, Ruth H. Bawn, Stephen R. Wedge, Christiane Riedinger, Christopher N. Johnson, Bernard T. Golding, Lynsey Fazal, Ian R. Hardcastle, Mladen Vinkovic, Claire E. Jennings, Jong Sook Ahn, Bian Zhang, Pamela A. Williams, Celine Cano, Suzannah J. Harnor, Ben Cons, Stephen J. Hobson, E. Anscombe, Jeffrey D. St. Denis, Steven Howard, David R. Newell, Emiliano Tamanini, Nicola E. Wilsher, Miller Duncan Charles, Huw D. Thomas, Timothy J. Blackburn, Martin E.M. Noble, Judith Reeks, Yan Zhao, Luke Bevan
Publikováno v:
Journal of Medicinal Chemistry. 64:4071-4088
Inhibition of murine double minute 2 (MDM2)-p53 protein-protein interaction with small molecules has been shown to reactivate p53 and inhibit tumor growth. Here, we describe rational, structure-guided, design of novel isoindolinone-based MDM2 inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd2c962765a3d64c4d7d02d50fd31b0d
https://doi.org/10.1021/acs.jmedchem.0c02188
https://doi.org/10.1021/acs.jmedchem.0c02188
Autor:
Michael Reader, Aurélie Courtin, Steven Howard, Nicola G. Wallis, Jonathan Shannon, Hugh Walton, Christopher William Murray, Joseph E. Coyle, Joanne M. Munck, Alison Jo-Anne Woolford, Torren M. Peakman, David C. Rees, James Edward Harvey Day, Charlotte Mary Griffiths-Jones, Marc O'Reilly, Alpesh Shah, David Norton, Valerio Berdini, Lynsey Fazal, Maria Grazia Carr, Charlotte East, Tom D. Heightman, Nicola E. Wilsher, Ildiko Maria Buck, Luke Bevan, Stuart Thomas Onions, Michael Cooke, Justyna Kucia-Tran, Sandra Muench, Nick Palmer, Sharna J. Rich, Vanessa Martins, David Cousin, Puja Pathuri, John P. Watts
Publikováno v:
Journal of medicinal chemistry. 64(16)
Aberrant activation of the mitogen-activated protein kinase pathway frequently drives tumor growth, and the ERK1/2 kinases are positioned at a key node in this pathway, making them important targets for therapeutic intervention. Recently, a number of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62d0e8543148c5c72af0eca510047c9f
https://pubmed.ncbi.nlm.nih.gov/34387469
https://pubmed.ncbi.nlm.nih.gov/34387469
Autor:
Neil T. Thompson, Charlotte Mary Griffiths-Jones, John Lyons, Vanessa Martins, Nicola E. Wilsher, Tom D. Heightman, Harpreet K Saini, Juan Castro, Stuart Thomas Onions, David Cousin, Nicola G. Wallis, Valerio Berdini, Nick Palmer, Puja Pathuri, Caroline Richardson, Christopher William Murray, Charlotte East, John P. Watts, Marc O'Reilly, Sharna J. Rich, Hugh Walton, James Edward Harvey Day, Aurélie Courtin, Brent Graham, David C. Rees, Hannah Braithwaite, Michael Cooke, Ildiko Maria Buck, Michael Reader, Sandra Muench, Megan Cassidy, Jonathan Shannon, Joanne M. Munck, Alison Jo-Anne Woolford, David Norton, Lynsey Fazal
Publikováno v:
Journal of Medicinal Chemistry. 61:4978-4992
Aberrant activation of the MAPK pathway drives cell proliferation in multiple cancers. Inhibitors of BRAF and MEK kinases are approved for the treatment of BRAF mutant melanoma, but resistance frequently emerges, often mediated by increased signaling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f64bcd2385197c9e1b7f9532e4d26523
https://doi.org/10.1021/acs.jmedchem.8b00421
https://doi.org/10.1021/acs.jmedchem.8b00421
Autor:
Christopher Hindley, Andrea Biondo, Kim-Hien Dao, Lynsey Fazal, Alpesh Shah, Martin Sims, Nicola Wilsher, Harold Keer, John Lyons
Publikováno v:
Molecular Cancer Therapeutics. 20:P112-P112
The inhibition of aberrant MAPK pathway activity is a clinically validated approach which has resulted in the approval of agents targeting tumors driven by activating mutations in BRAF and KRAS. Although the overall response rate to MAPK-targeting ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed0b5bd77475b1f54111576033fdd9c9
https://doi.org/10.1158/1535-7163.targ-21-p112
https://doi.org/10.1158/1535-7163.targ-21-p112
Autor:
Nicola G. Wallis, John Lyons, Andrea Biondo, Harold N. Keer, Christopher J. Hindley, Martin Sims, Harpreet K Saini, Keisha Hearn, Nicola E. Wilsher, Kim-Hien Dao, Roberta Ferraldeschi, Joanne M. Munck, Matthew Davis, Lynsey Fazal, Vanessa Martins
Publikováno v:
Cancer Research. 81:1661-1661
Whilst mitogen-activated protein kinase (MAPK) pathway inhibitors are approved therapies in mutant-BRAF driven cancers and have demonstrated a high response rate in the clinic, the duration of response is often short-lived. Approaches targeting the i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9539c21be91a9da3ce5057a00a7961bb
https://doi.org/10.1158/1538-7445.am2021-1661
https://doi.org/10.1158/1538-7445.am2021-1661
Autor:
Harold N. Keer, John Lyons, Nicola E. Wilsher, Nicola G. Wallis, Christopher J. Hindley, Alpesh Shah, Joanne M. Munck, Lynsey Fazal, Vanessa Martins
Publikováno v:
Blood. 136:7-8
Oncogenic mutations in genes such as the RAS family (KRAS, NRAS or HRAS) or receptor tyrosine kinases (RTKs) drive tumor growth through aberrant activation of the mitogen activated protein kinase (MAPK) signaling pathway. Acute myeloid leukemia (AML)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a1ff29a2a0279b2365c9fb840941ef3
https://doi.org/10.1182/blood-2020-139175
https://doi.org/10.1182/blood-2020-139175
Autor:
H. Ochiiwa, Nicola E. Wilsher, Joanne M. Munck, M. Jones, N. Kandola, Nicola G. Wallis, Lynsey Fazal, Sandra Muench, Christopher J. Hindley, John C. Lyons, J. Brothwood, Keisha Hearn, Vanessa Martins, S. Wagner, C.N. Johnson, Y. Nakatsuru, Alpesh Shah, Tomoko Smyth, K. Miyadera, Harpreet K Saini
Publikováno v:
European Journal of Cancer. 138:S44-S45
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02d56d515451060ae887919d8f7c4d3a
https://doi.org/10.1016/s0959-8049(20)31194-1
https://doi.org/10.1016/s0959-8049(20)31194-1